RxDoctor Payments DataLook up a doctor →

Khalid Ahmed, MD

Internal Medicine · Flint, MINPI 1619965175

Payments from drug & device makers

$173,947in general payments, 2019–2025

Across 307 payments — averaging $566.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Research & Development, LLC$76K
  • Novartis$59K
  • Pfizer$18K
  • Hikma Pharmaceuticals USA$9K
  • Boehringer Ingelheim$4K
  • GSK$4K
  • plus $4K from 40 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Janssen Research & Development, LLC20$75,622
Novartis30$59,052
Pfizer(2 entities)29$17,909
Hikma Pharmaceuticals USA1$8,584
Boehringer Ingelheim6$4,365
GSK8$3,955
AbbVie(2 entities)51$740
Gilead22$481
AstraZeneca(2 entities)11$461
Otsuka America Pharmaceutical, Inc.20$344
Amgen(2 entities)17$277
Johnson & Johnson3$229
Biohaven Pharmaceuticals, Inc.2$199
Vanda Pharmaceuticals Inc.7$174
Novo Nordisk8$142
E.r. Squibb & Sons, L.L.C.7$111
Lilly USA, LLC5$110
Exact Sciences4$99
Nestle Healthcare Nutrition Inc.6$91
Sanofi-aventis U.S. LLC5$91
Teva Pharmaceuticals USA, Inc.4$87
Merck3$81
Sunovion Pharmaceuticals Inc.1$80
Axsome Therapeutics, Inc.4$67
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)4$66
Actelion Pharmaceuticals US, Inc.2$58
Astellas Pharma US Inc3$49
Lundbeck LLC2$38
Smith+Nephew2$37
Azurity Pharmaceuticals, Inc.2$33
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC2$31
Global Blood Therapeutics, Inc.2$28
Brainsway USA Inc1$27
Abbott1$24
Biohaven Pharmaceutical Holding Company Ltd.1$23
Eisai Inc.1$22
UCB, Inc.1$21
Alkermes, Inc.1$20
Daiichi Sankyo Inc.1$20
Dexcom, Inc.1$17
Mylan Specialty L.p.1$15
Seqirus USA Inc1$14
Inari Medical, Inc.1$14
Takeda Pharmaceuticals U.S.A., Inc.1$14
Evoke Pharma, Inc.1$13
Ultragenyx Pharmaceutical Inc.1$12

How this compares

$173,947 in reported general payments places this provider in the 95th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan →

Medicare billing

Part B allowed, 2024
$83,550
Medicare patients
342
Services billed
1,045

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in Flint

See the full list for Michigan →

Where these figures come from

Is this you, or does something look wrong? →